TY - JOUR T1 - Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative JF - medRxiv DO - 10.1101/2022.03.28.22273040 SP - 2022.03.28.22273040 AU - Guillaume Butler-Laporte AU - Gundula Povysil AU - Jack A. Kosmicki AU - Elizabeth T Cirulli AU - Theodore Drivas AU - Simone Furini AU - Chadi Saad AU - Axel Schmidt AU - Pawel Olszewski AU - Urszula Korotko AU - Mathieu Quinodoz AU - Elifnaz Çelik AU - Kousik Kundu AU - Klaudia Walter AU - Junghyung Jung AU - Amy D Stockwell AU - Laura G Sloofman AU - Daniel M. Jordan AU - Ryan C. Thompson AU - Diane Del Valle AU - Nicole Simons AU - Esther Cheng AU - Robert Sebra AU - Eric E. Schadt AU - Seunghee Schulze-Kim AU - Sacha Gnjatic AU - Miriam Merad AU - Joseph D. Buxbaum AU - Noam D. Beckmann AU - Alexander W. Charney AU - Bartlomiej Przychodzen AU - Timothy Chang AU - Tess D Pottinger AU - Ning Shang AU - Fabian Brand AU - Francesca Fava AU - Francesca Mari AU - Karolina Chwialkowska AU - Magdalena Niemira AU - Szymon Pula AU - J Kenneth Baillie AU - Alex Stuckey AU - Antonio Salas AU - Xabier Bello AU - Jacobo Pardo-Seco AU - Alberto Gómez-Carballa AU - Irene Rivero-Calle AU - Federico Martinón-Torres AU - Andrea Ganna AU - Konrad J Karczewski AU - Kumar Veerapen AU - Mathieu Bourgey AU - Guillaume Bourque AU - Robert JM Eveleigh AU - Vincenzo Forgetta AU - David Morrison AU - David Langlais AU - Mark Lathrop AU - Vincent Mooser AU - Tomoko Nakanishi AU - Robert Frithiof AU - Michael Hultström AU - Miklos Lipcsey AU - Yanara Marincevic-Zuniga AU - Jessica Nordlund AU - Kelly M. Schiabor Barrett AU - William Lee AU - Alexandre Bolze AU - Simon White AU - Stephen Riffle AU - Francisco Tanudjaja AU - Efren Sandoval AU - Iva Neveux AU - Shaun Dabe AU - Nicolas Casadei AU - Susanne Motameny AU - Manal Alaamery AU - Salam Massadeh AU - Nora Aljawini AU - Mansour S. Almutairi AU - Yaseen M. Arabi AU - Saleh A. Alqahtan AU - Fawz S. Al Harthi AU - Amal Almutairi AU - Fatima Alqubaishi AU - Sarah Alotaibi AU - Albandari Binowayn AU - Ebtehal A. Alsolm AU - Hadeel El Bardisy AU - Mohammad Fawzy AU - COVID-19 Host Genetics Initiative AU - DeCOI Host Genetics Group AU - GEN-COVID Multicenter Study (Italy) AU - Mount Sinai Clinical Intelligence Center AU - GEN-COVID consortium (Spain) AU - GenOMICC Consortium AU - Japan COVID-19 Task Force AU - Regeneron Genetics Center AU - Daniel H Geschwind AU - Stephanie Arteaga AU - Alexis Stephens AU - Manish J. Butte AU - Paul C. Boutros AU - Takafumi N. Yamaguchi AU - Shu Tao AU - Stefan Eng AU - Timothy Sanders AU - Paul J. Tung AU - Michael E. Broudy AU - Yu Pan AU - Alfredo Gonzalez AU - Nikhil Chavan AU - Ruth Johnson AU - Bogdan Pasaniuc AU - Brian Yaspan AU - Sandra Smieszek AU - Carlo Rivolta AU - Stephanie Bibert AU - Pierre-Yves Bochud AU - Maciej Dabrowski AU - Pawel Zawadzki AU - Mateusz Sypniewski AU - Elżbieta Kaja AU - Pajaree Chariyavilaskul AU - Voraphoj Nilaratanakul AU - Nattiya Hirankarn AU - Vorasuk Shotelersuk AU - Monnat Pongpanich AU - Chureerat Phokaew AU - Wanna Chetruengchai AU - Katsuhi Tokunaga AU - Masaya Sugiyama AU - Yosuke Kawai AU - Takanori Hasegawa AU - Tatsuhiko Naito AU - Ho Namkoong AU - Ryuya Edahiro AU - Akinori Kimura AU - Seishi Ogawa AU - Takanori Kanai AU - Koichi Fukunaga AU - Yukinori Okada AU - Seiya Imoto AU - Satoru Miyano AU - Serghei Mangul AU - Malak S Abedalthagafi AU - Hugo Zeberg AU - Joseph J Grzymski AU - Nicole L Washington AU - Stephan Ossowski AU - Kerstin U Ludwig AU - Eva C Schulte AU - Olaf Riess AU - Marcin Moniuszko AU - Miroslaw Kwasniewski AU - Hamdi Mbarek AU - Said I Ismail AU - Anurag Verma AU - David B Goldstein AU - Krzysztof Kiryluk AU - Alessandra Renieri AU - Manuel A.R. Ferreira AU - J Brent Richards Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/20/2022.03.28.22273040.abstract N2 - Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41×10−7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.Author Summary COVID-19 clinical outcomes vary immensely, but a patient’s genetic make-up is an important determinant of how they will fare against the virus. While many genetic variants commonly found in the populations were previously found to be contributing to more severe disease by the COVID-19 Host Genetics Initiative, it isn’t clear if more rare variants found in less individuals could also play a role. This is important because genetic variants with the largest impact on COVID-19 severity are expected to be rarely found in the population, and these rare variants require different technologies to be studies (usually whole-exome or whole-genome sequencing). Here, we combined sequencing results from 21 cohorts across 12 countries to perform a rare variant association study. In an analysis comprising 5,085 participants with severe COVID-19 and 571,737 controls, we found that the gene for toll-like receptor 7 (TLR7) on chromosome X was an important determinant of severe COVID-19. Importantly, despite being found on a sex chromosome, this observation was consistent across both sexes.Competing Interest StatementSee Suppl. Table 2.Funding StatementSee Suppl. Tables 2-4.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:See Suppl. Table 1-2.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe exome-wide burden test summary statistics are available in the Supplements. The single variant association studies summary statistics will be made available openly on the GWAS Catalog following publication. ER -